2020 Annual General Meeting
CEO Presentation

18 September 2020

Amplia Therapeutics Limited

Amplia
Exposing cancer. Enhancing treatment.

Disclaimer

The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited ("Amplia") in any jurisdiction. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation contains forward-looking statements which can be identified by the use of words such as "may", "should", "will", "expect", "anticipate", "believe", "estimate", "intend", "scheduled" or "continue" or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Amplia, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Amplia's acquired product pipeline. Actual results from clinical trials may vary from those shown.

Company Highlights

Developing small molecule drugs against Focal Adhesion Kinase (FAK) for two, significant disease areas:

- **cancer** – combination therapy in hard-to-treat solid tumours
- **fibrosis** – prevention and treatment

Orphan Drug Designations (ODDs) for both pancreatic cancer and idiopathic pulmonary fibrosis

Range of commercial opportunities for partnering, licensing and co-development

First Phase 1 clinical trial starting in October 2020

Data from Phase 1 will be relevant for multiple cancer and fibrotic disease indications

Investigational New Drug (IND) designation and Phase 2 clinical trial program targeted in 2021

Amplia FAKi's provide a broad opportunity set

AMP945 and **AMP886** provide Amplia with several commercial opportunities

Amplia is taking three approaches realise these opportunities:

1. **take AMP945 into clinical development** for pancreatic cancer and idiopathic lung fibrosis (both granted Orphan Drug Designations by the FDA)

2. **license, partner or co-develop** other applications for AMP945 including other cancer combination therapies, fibrotic diseases, uveal melanoma

3. **seek partners** for co-development or licensing of AMP886 to treat wet AMD, cancer or fibrotic diseases



Company snapshot[1]

Shares	106.3M
Market cap	$16.0M
Options	14.1M
Cash [2]	$4.0M
Last qtr burn [3]	($0.4M)
Listed	May 2018 (RTO)
Headquarters	Melbourne
Board	Warwick Tong (Chair) John Lambert (MD) Robert Peach (NED) Chris Burns (NED)
Substantial institutional holders	Platinum – 16.2% Blueflag Holdings – 7.1%

[1] as at 15 Sep 2020
[2] cash held at 31 Aug 2020
[3] quarter ending 30 Jun 2020

ATX Price and Volume – 12 months

price	$0.15
12mth high - low	$0.22 - $0.04
av. daily volume	260,000

Achievements in FY2020

Apr 2019 – European patent covering AMP945 until 2034 granted

Jun 2019 – Preliminary dose-finding animal toxicology studies completed

Jun 2019 – Dr John Lambert appointed as CEO

Jul 2019 – Preclinical data on use of AMP945 to treat squamous cell carcinoma reported

Jul 2019 – Placement and rights issue raising $1.2M at $0.10/share

Aug 2019 – Positive data demonstrating high level of selectivity of AMP945 for FAK target

Sep 2019 – Kilogram-scale batch of clinical grade AMP945 released for use in clinical testing

Jan 2020 – Placement raising $930K at $0.07/share corner-stoned by Platinum

Jan 2020 – Restructure and streamlining of Board completed

Feb 2020 – Prof. Paul Timpson joins Scientific Advisory Board

Mar 2020 – Orphan Drug Designation awarded for pancreatic cancer

Achievements since 30 Mar 2020

May 2020 – Orphan Drug Designation awarded for idiopathic pulmonary fibrosis

Jun 2020 – Completed toxicology studies required to support Phase 1 clinical trial

Jul 2020 – Rights Issue raising $4.0M at $0.10/share

Aug 2020 – Dr Mark Devlin appointed as Chief Scientific Officer

Sep 2020 – Received ethics clearance to conduct Phase 1 trial in healthy volunteers



Phase 1 Trial of AMP945

First clinical trial of AMP945 will commence dosing in October 2020:

- GMP clinical manufacture complete (kg scale)
- Preclinical toxicology studies complete
- Nucleus Network selected to manage trial being conducted at the Alfred Hospital
- Clearance received from Human Research Ethics Committee (HREC)

Phase 1 safety trial of orally administered AMP945 in healthy volunteers:

- Single Australian site
- 64 volunteers, cost of ~$2M
- Single ascending dose (SAD) and multiple ascending dose (MAD)
- Forecast 6-9 months to complete

Purpose of the trial:

- Initial assessment of the clinical safety and pharmacokinetics of AMP945
- Platform for future clinical studies in cancer and fibrosis patients

AMP945 – treatment of solid tumours

Pancreatic cancer

- FDA Orphan Drug Designation for AMP945 in the treatment of pancreatic cancer received in March 2020
- Collaboration with Prof. Paul Timpson at the Garvan Institute to assess novel dosing regimes and combination therapies for pancreatic cancer
- These studies will help guide future clinical trials in patients with pancreatic cancer

Other cancers

- Amplia plans to perform preclinical studies to evaluate combining AMP945 with other cancer drugs including MEK inhibitors
- These studies will inform the structure and design on Amplia's Phase 2 clinical program



FAK in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a devastating, progressive disease caused by the build-up of fibrotic tissue in the lung which affects 3M people worldwide, including 130,000 in the US

Left untreated, the median survival time is 2-3 years, with lung transplantation the only treatment option currently available that improves outcomes

Approved antifibrotic drugs (pirfenidone and nintedanib) slow the progression of the disease by ~50%, but are unable to prevent the eventual loss of lung function:

- increase median life expectancy by 2½ years
- quality of life for end-stage disease remains very poor

FAK has a pivotal role in the biochemical pathways regulating the development and progression of fibrosis in the lungs

AMP945 – 18-month development plan



Upcoming targeted milestones

- **Oct 2020 -** Initiate dosing for SAD arm of Phase 1 clinical trial
- **Dec 2020 -** Initiate dosing for MAD arm of Phase 1 clinical trial
- **Q2 2021 -** Selection of first indication for Phase 2 based on preclinical combo studies
- **Q2 2021 -** Headline data from both SAD and MAD arms of Phase 1 clinical study
- **Q3 2021 -** File Investigational New Drug (IND) Application for AMP945 with FDA
- **Q4 2021 -** Receive IND designation for AMP945
- **H2 2021 -** Initiate Phase 2 program for AMP945 in cancer and IPF

Ampliа

Exposing cancer. Enhancing treatment.

ampliatx.com